CTCs in a Study of Docetaxel and Prednisone ± Lenalidomide in Metastatic Castration-Resistant Prostate Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulating Tumor Cells in a Phase 3 Study of Docetaxel and Prednisone With or Without Lenalidomide in Metastatic Castration-Resistant Prostate Cancer
Eur Urol 2017 Feb 01;71(2)168-171, NJ Vogelzang, K Fizazi, JM Burke, R De Wit, J Bellmunt, TE Hutson, E Crane, WR Berry, K Doner, JD Hainsworth, PJ Wiechno, K Liu, MF Waldman, A Gandhi, D Barton, U Jungnelius, A Fandi, CN Sternberg, DP PetrylakFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Advanced Prostate Cancer Center of Excellence
Visit our Advanced Prostate Cancer Center of Excellence for additional, in-depth coverage.